article nine

Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab (Remicade): first experiences
 
H G Kraetsch, C Antoni, J R Kalden, B Manger
Department for Internal Medicine III with Institute for Clinical Immunology,
Friedrich-Alexander University of Erlangen, Nuremberg, Germany


Correspondence to: Dr H Kraetsch, Department of Internal Medicine III with
Institute for Clinical Immunology, Krankenhausstr 12, D-91054 Erlangen,
Germany
hans-georg.kraetsch@med3.imed.uni-erlangen.de

Accepted for publication 28 June 2001


OBJECTIVE To test the efficacy of infliximab in the treatment of patients
with severe and active adult onset Still's syndrome (AOSD) despite
conventional immunosuppressive therapy.


PATIENTS AND METHODS  Six patients with the diagnosis of AOSD according to the Yamagushi criteria of 1992 were treated with infliximab. All patients had
severe disease with high clinical and serological activity. Patients were
treated initially with high dose steroids or more intensive
immunosuppressive therapy.

Two patients had a history of multiple disease
modifying antirheumatic drug (DMARD) treatments. One patient had a history
of three years of AOSD with fever, chills, pleural and pericardial
effusions, and hepatosplenomegaly. Despite these treatments, he developed
increasing serological signs of inflammation and arthritis of both hips and
peripheral joints. Another patient had a history of five years of AOSD with
oligoarthritis, myalgias, and recurrent fever despite multiple DMARD
treatment, including cyclophosphamide pulse therapy. Our patients with AOSD
presented with massive polyarthralgias, polyarthritis, splenomegaly or
hepatomegaly, the typical rash, sore throat, weight loss, serositis,
continuing fever, leucocytosis, and raised C reactive protein (CRP),
erythrocyte sedimentation rate (ESR), and ferritin levels. Four patients
with early onset of the disease, fulfilling the diagnostic criteria for AOSD
and a clinical and serological high disease activity, were included in our
pilot study without any further DMARD treatment apart from the initial
steroid treatment. Reduction of established treatment, mainly with steroids,
caused a relapse of the disease in all our patients. Patients then received
3-5 mg/kg infliximab on weeks 0, 2, and 6, continuing with intervals of 6-8
weeks depending on the patient's individual disease activity.


RESULTS In all patients, fever, arthralgias, myalgias, hepatosplenomegaly,
and the rash resolved after the first courses of treatment with infliximab.
All serological variables (CRP, ESR, hyperferritinaemia) returned to normal.
After three courses of infliximab infusions, splenomegaly could not be
detected in any of our patients. One patient still had severe pain in the
left hip caused by hip postarthritic osteoarthrosis, requiring hip
replacement. After three courses of treatment with infliximab, splenomegaly
could not be detected in any of our patients. Up to now, our patients have
received infliximab infusion treatment for between five and 28 months.
Throughout this period all patients have continued to benefit from this
treatment, with improvement in their clinical symptoms, joint counts, and
serological disease activity. One of our patients had a moderate infusion
reaction during the second treatment. The infusion was discontinued for one
hour and then was resumed with no further problems.


CONCLUSION The disease improved remarkably in all six patients with AOSD
after treatment with infliximab, also in the early stage of AOSD. These
preliminary data suggest the potential therapeutic benefit of anti-tumour
necrosis factor treatment in AOSD.

Back Home Next

 

DISCLAIMER:

The materials and information on this server are intended for educational and informational purposes only. The materials and information are not intended to replace the services of a trained health professional or to be a substitute for medical advice of physicians and/or other health care professionals. The International Still's Disease Foundation is not engaged in rendering medical or professional medical services. You should consult your physician on specific medical questions, particularly in matters requiring diagnosis or medical attention. The International Still's Disease Foundation makes no representations or warranties with respect to any treatment, action, application medication or preparation by any person following the information offered or provided within this website.  Any information used from other websites was done so with permission from each site, with an exception to those of "public domain", whereas we believe any site without a cited reference was a "public domain site" and for our use.  The International Still's Disease Foundation is a non-profit organization.   This page was last updated on June 13, 2002

Copyright© 1999-2002 International Still's Disease Foundation